The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...

When it comes to bladder cancer, it’s important to note the differences between muscle-invasive and non-muscle-invasive bladder cancer, as it can affect the staging of the cancer. The “stage” (spread) ...

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...

In December 2025, Astellas Pharma and Pfizer reported that their Phase 3 EV-304 trial of PADCEV plus Keytruda in muscle-invasive bladder cancer achieved statistically significant improvements in event ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s ...

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its ...

Theralase Technologies ( ($TSE:TLT) ) has provided an announcement. Theralase Technologies has closed a non-brokered private placement of ...

Kolschowsky Research and Education Institute at Sarasota Memorial Hospital is seeking candidates diagnosed with ...

The phase 3, open-label, single arm BOND-003 trial also evaluated cretostimogene in cohort P with papillary-only high-grade NMIBC who failed prior BCG therapy.